Catalyst Pharmaceuticals (CPRX) Tops Q4 EPS by 38c, Beats on Revenue; Offers FY25 Revenue Guidance
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Price: $31.38 --0%
EPS Growth %: -30.9%
Financial Fact:
General and administrative: 1.42M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -30.9%
Financial Fact:
General and administrative: 1.42M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q4 EPS of $0.70, $0.38 better than the analyst estimate of $0.32. Revenue for the quarter came in at $141.8 million versus the consensus estimate of $133.68 million.
GUIDANCE:
Catalyst Pharmaceuticals sees FY2025 revenue of $545-565 million, versus the consensus of $558 million.
For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
- KeyCorp (KEY) files for 158.72M share offering by selling stockholders
- S&P Global (SPGI) Declares $0.97 Quarterly Dividend; 1% Yield
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
